MedTrace Logo

The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics

NCT02956278 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2020-06-23

Study results available
· View outcomes & findings →

Summary

Subjects will undergo a placebo and allopurinol phase to better understand the effects of the reduced function BCRP Q141K variant on allopurinol pharmacokinetics and pharmacodynamics.

Conditions

  • Chronic Gout
  • Hyperuricemia

Interventions

DRUG

Allopurinol

OTHER

Placebo

lactose placebo pill

Sponsors & Collaborators

Principal Investigators

  • Kathleen Giacomini, PhD · University of California, San Francisco

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2018-03-31
Completion
2018-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02956278 on ClinicalTrials.gov